Kiniksa Pharmaceuticals International (KNSA) Cash from Operations Growth (3y) (2020 - 2026)
Kiniksa Pharmaceuticals International (KNSA) Cash from Operations Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 34.90% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -9.94% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -10.80% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 7.32% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -26.33% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 46.81% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 27.85% |
| 10 | Kiniksa Pharmaceuticals International | 4.82 Bn | 4.36 Bn | 193.47 Mn | 139.66% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 139.66% |
| Dec 31, 2025 | 88.10% |
| Sep 30, 2025 | -18.43% |
| Jun 30, 2025 | 77.48% |
| Mar 31, 2025 | 37.61% |
| Dec 31, 2024 | 44.13% |
| Sep 30, 2024 | 57.19% |
| Jun 30, 2024 | 28.73% |
| Mar 31, 2024 | 28.05% |
| Dec 31, 2023 | 28.16% |
| Sep 30, 2023 | 35.63% |
| Jun 30, 2023 | 49.59% |
| Mar 31, 2023 | 48.80% |
| Dec 31, 2022 | 21.76% |
| Sep 30, 2022 | 60.31% |
| Jun 30, 2022 | 42.74% |
| Mar 31, 2022 | 16.49% |
| Dec 31, 2021 | 11.92% |
| Sep 30, 2021 | -11.65% |
| Jun 30, 2021 | -29.36% |